INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharm...

NEW YORK, March 13, 2015 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NasdaqGM: ACRX).

The investigation focuses on whether the Company and its executives violated federal securities laws by making materially false and misleading statements regarding the Company's business, operations, and prospects.

On March 9, 2015, AcelRx announced that it has received correspondence from the United States Food and Drug Administration advising that, in addition to the bench testing and Human Factor studies it has performed for its drug Zalviso, the New Drug Application for Zalviso will require a new clinical study to assess the risk of inadvertent dispensing and the overall risk of dispensing failures.

Following this news, AcelRx stock declined by $3.23 per share, or nearly 37%, to close on March 9, 2015 at $5.51 per share. 

Request more information now by clicking here: www.faruqilaw.com/ACRX. There is no cost or obligation to you.

Take Action

If you invested in AcelRx stock or options through March 8, 2015 and would like to discuss your legal rights, visit www.faruqilaw.com/ACRX.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [e-mail].  Faruqi & Faruqi, LLP also encourages anyone with information regarding AcelRx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
[e-mail]
Telephone: [phone] or [phone]

Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/investor-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-acelrx-pharmaceuticals-inc-acrx-to-contact-the-firm-300050419.html

SOURCE Faruqi & Faruqi, LLP

Copyright 2015 PR Newswire